NYSE:HAE - Haemonetics Stock Price, Price Target & More

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Haemonetics declared that its board has authorized a stock buyback plan on Tuesday, February 6th 2018, which allows the company to buyback $260,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Stock buyback plans are often an indication that the company's management believes its stock is undervalued.

Haemonetics (NYSE:HAE) issued its quarterly earnings data on Tuesday, May, 8th. The medical instruments supplier reported $0.43 EPS for the quarter, hitting the consensus estimate of $0.43. The medical instruments supplier earned $233.55 million during the quarter, compared to analyst estimates of $226.63 million. Haemonetics had a net margin of 5.04% and a return on equity of 12.71%. The company's quarterly revenue was up 2.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.39 earnings per share. View Haemonetics' Earnings History.

Haemonetics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Haemonetics.

Haemonetics issued an update on its FY19 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $2.00-2.30 for the period, compared to the Thomson Reuters consensus estimate of $2.09.

6 analysts have issued 12 month target prices for Haemonetics' stock. Their forecasts range from $50.00 to $100.00. On average, they anticipate Haemonetics' stock price to reach $81.40 in the next twelve months. View Analyst Ratings for Haemonetics.

Haemonetics saw a drop in short interest during the month of April. As of April 13th, there was short interest totalling 884,267 shares, a drop of 32.0% from the March 30th total of 1,300,931 shares. Based on an average trading volume of 435,043 shares, the short-interest ratio is presently 2.0 days. Approximately 1.7% of the company's stock are sold short.

Some companies that are related to Haemonetics include Abiomed (ABMD), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Penumbra (PEN), Cantel Medical (CMD), Insulet (PODD), Globus Medical (GMED), Merit Medical Systems (MMSI), NovoCure (NVCR), NuVasive (NUVA), Nevro (NVRO) and iRhythm (IRTC).

News coverage about HAE stock has trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Haemonetics earned a daily sentiment score of 0.07 on Accern's scale. They also gave news articles about the medical instruments supplier an impact score of 47.10 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Haemonetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.96%), Wells Fargo & Company MN (3.58%), Neuberger Berman Group LLC (3.25%), Dimensional Fund Advisors LP (2.90%), Victory Capital Management Inc. (2.82%) and Millennium Management LLC (2.21%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Pedro P Granadillo, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote and Willaim P Burke. View Institutional Ownership Trends for Haemonetics.

HAE stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Point72 Asset Management L.P., Neuberger Berman Group LLC, Wells Fargo & Company MN, Segall Bryant & Hamill LLC, WINTON GROUP Ltd, Royal Bank of Canada and Schwab Charles Investment Management Inc.. Company insiders that have sold Haemonetics company stock in the last year include Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Pedro P Granadillo, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote and Willaim P Burke. View Insider Buying and Selling for Haemonetics.

HAE stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., BlackRock Inc., Columbus Circle Investors, OppenheimerFunds Inc., Federated Investors Inc. PA, Picton Mahoney Asset Management and Allianz Asset Management GmbH. View Insider Buying and Selling for Haemonetics.

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HAE stock can currently be purchased for approximately $90.92.

Haemonetics has a market capitalization of $4.75 billion and generates $903.92 million in revenue each year. The medical instruments supplier earns $45.57 million in net income (profit) each year or $1.87 on an earnings per share basis. Haemonetics employs 3,107 workers across the globe.

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]